North Sea Therapeutics raises US$40m in Se...NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate. more ➔
Merck and 4SC collaborate in immunooncolog...4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat. more ➔
Novo Holdings invest US$12m in AMR compani...Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund. more ➔
Fighting sepsis mortality Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality. more ➔
Antabio SAS advances cystic fibrosis progr... Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients more ➔
Hydrogel fights wound infection and inflam... Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds. more ➔
British diagnostics play OBD lands contrac...The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic … more ➔
Truffle’s BioMedTech fund filled wit...Paris-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach. more ➔
Cellestia: €20m to get to Phase IIBasel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million. more ➔
Biomarker identifies residual congestion i...Data from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients. more ➔
